CORD-19:12fbecd4737a9af7b8fab5267094fdfa754f25fa / 18839-19053 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/12fbecd4737a9af7b8fab5267094fdfa754f25fa","sourcedb":"CORD-19","sourceid":"12fbecd4737a9af7b8fab5267094fdfa754f25fa","text":"The main hurdle to the development of new and improved adjuvants has been safety, because vaccines that are to be used in healthy individuals will need to induce minimal adverse effects to prove acceptable for use.","tracks":[{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T102","span":{"begin":0,"end":214},"obj":"Sentence"}],"attributes":[{"subj":"T102","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T102","span":{"begin":0,"end":214},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T102","pred":"source","obj":"CORD-19-Sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19_Custom_license_subset","color":"#ab93ec","default":true},{"id":"CORD-19-Sentences","color":"#94ec93"}]}]}}